BenevolentAl Therapeutics Pipeline and Triage
Target Triage
The Benevolent Platform TM provides a systematic process for
target triage sharing insights and context for each prediction
Biological
rationale
Safety
Novelty
Progressibility
Hypotheses
Precision
medicine
Druggability
Target List: Mitochondrion Health focus for PD (Demo) - Mitochondrion Health focus for PD (Demo) 179 targets in total poaded from an unknown source)
26 results
13 Uncen 13 Mach
Sort by
Sort by
QFind target
Target Symbol
clear all
Your criteria for triage
Ligendebility must be 3 or 44
Programs Panon's Disease Demo Da
CSNK2A1 casein kinase 2 alpha 1
Ligandy&Selety-class (out of 4 Thetic Evidence of Chemical Opportunity-of
Bogical Rationale-class 2 of Target Expression-class 1
Uncertain
Change Your comment (can be edited when changing target decision)
Filter by context
VCP valosin containing protein
Mechanism
Ligand-fety-clef Therapeutic Evidence-Chemical Opportunity-class1 of
logical Rationale-class&of Target Expression-f
Filter by triage status
Match
Change Your comment can be edited when changing target decision
Triage Status
Recommendation/Decision
Filter by criteria
Has suitable tool compound b
Has suitable tool compound in...
clear
EPAS1 endothelial PAS domain protein 1
Ligandabiy-stof Safety-class 3 out of 4) Therapedic Evidence-cles 3nt of Chemical Opportunity-class 1 out of 4
logical Rationale-less 1 out of
Target Expression-of
Uncertain
Change
Your comment (can be edited when changing target decision)
Screenshot shows Company triage board. 'Company internal drug progamme statistics
Visualise
G
51
Target hypotheses undergo expert review with criteria
that are tailored to the programme
Recommended classifications are made to guide triage
decisions using the Knowledge Graph and information
presented in the triage tool
Decisions are captured in a structured and unstructured
manner to both ensure an audit trail and allow the system
to learn over time
Targets that pass triage are progressed into validation
In a recent deployment, 39% of targets were
progressed into experimental testing.
Of those not progressed; 22% were already known to
our program experts, 24% were deemed to have safety
concerns and 15% did not have sufficient supporting
evidence.
Benevolent 22
ΑΙView entire presentation